Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non-muscleinvasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Gu erin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial.
JOURNAL OF CLINICAL ONCOLOGY(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要